Atai Life Sciences BV

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company, which engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. Its sound financial position and deep clinical pipeline appear to have sparked a wave of bargain buying this week.

Why Atai Life Sciences Stock Stormed Higher This Week

NEW YORK and BERLIN, March 24, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported fourth quarter and full year 2022 financial results and provided clinical pipeline highlights.

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

The psychedelic drug boom may be taking off, but one company in the space is trimming its workforce. Atai Life Sciences (NASDAQ: ATAI ) just announced it has laid off roughly 30% of its staff.

Atai Layoffs 2023: What to Know About the Latest ATAI Job Cuts

NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, provided key clinical pipeline and corporate updates.

atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

NEW YORK and BERLIN, March 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Cowen 43rd Annual Health Care Conference.

atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

Sorrento Therapeutics Inc

Wall Street is bullish on these two beaten-down healthcare stocks.

Wall Street Thinks These 2 Penny Stocks Could Go Parabolic

COMPASS Pathways

Cybin

Ameri Holdings

GH Research PLC

Mind Medicine MindMed

Advisorshares Psychedelics ETF

Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.

The 7 Most Promising Psychedelic Stocks to Buy in February

atai Life Sciences N.V. (ATAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted.

Down -34.59% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI)

atai Life Sciences N.V. (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

atai Life Sciences N.V. (ATAI) Upgraded to Buy: Here's What You Should Know

Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?

Psychedelic Sunday: Competitive Strategies

Seelos Therapeutics

What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management.

Scrutinizing Psychedelic Stocks

Atai Life Sciences' ketamine-based therapy failed to help patients with depression in a mid-stage trial.

The stock of psychedelics giant Atai is tumbling after a treatment failed to help patients in a trial

atai Life Sciences (NASDAQ:ATAI) shares tumbled more than 40% in pre-market trading on Friday after the company reported disappointing results from its subsidiary Perception Neuroscience's Phase 2a clinical trial of PCN-101 (R-ketamine), a stereoisomer of ketamine, for treatment-resistant depression. The biopharmaceutical company said in a statement that while PCN-101 demonstrated signs of efficacy across all time points out to two weeks, the trial did not meet its primary endpoint of a statistically significant change from baseline in participants' Montgomery-Åsberg Depression Rating Scale (MADRS) score at 24 hours compared to placebo.

atai Life Sciences shares plummet as r-ketamine candidate fails to meet primary endpoint in Phase 2a trial

Shares of Atai Life Sciences NV ATAI, -2.59% tumbled about 44% in premarket trading on Friday after the company said a Phase 2a clinical trial evaluating a ketamine therapy for treatment-resistant depression did not meet the primary endpoint. Atai's stock has declined 60.1% over the past year, while the S&P 500 SPX, -1.16% is down 19.0%.

Atai says its depression treatment failed in a mid-stage clinical trial

NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health, announced that, while PCN-101 (R-ketamine) demonstrated signals of efficacy across all timepoints out to two weeks, Perception Neuroscience's Phase 2a clinical trial did not meet its primary endpoint of a statistically significant change from baseline in participants' MADRS (Montgomery-Åsberg Depression Rating Scale) score at 24 hours compared to placebo.

atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression

-   This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics, and analgesic activity of KUR-101

atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101

SNDL Inc.

Tilray Brands

Stocks with big upside potential often have significant risks, too.

3 (Risky) Tricks for Finding Monster Growth Stocks

NEW YORK and BERLIN, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the initiation of its Phase 2b proof-of-concept clinical trial for RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS), a condition for which there are currently no FDA-approved treatments.

atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia

NEW YORK and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- atai Impact, the philanthropic arm of atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), today announced the first cohort of the atai Fellowship Fund in Psychedelic Neuroscience (the “Fellowship Fund”) at Massachusetts General Hospital (“MGH”) Center for the Neuroscience of Psychedelics. The $2 million Fellowship Fund was announced in December 2021 to facilitate research into the potential of psychedelics to address unmet patient needs in mental health and support promising graduate students and other trainees in furthering their professional careers in this emerging field.

The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital

Biogen

SAGE Therapeutics

Atai, Biogen, and Sage are working to develop new treatments for mental illness.

3 Biotech Stocks Aiming to Reinvent Mental Health Treatment

Major positive shifts are happening, but the field faces new headwinds too.

3 Big Trends Shaking Up Psychedelic Stocks

- Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and Co-chair of the Global Business Development Committee -

atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer

Atai Life Sciences N.V. (NASDAQ:ATAI ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Stephen Bardin - Chief Financial Officer Florian Brand - Chief Executive Officer and Co-Founder Srini Rao - Chief Scientific Officer and Co-Founder Conference Call Participants Andrew Tsai - Jefferies Ritu Baral - Cowen Stephen Bardin Hi, everyone and welcome to the Atai Life Sciences Third Quarter Earnings Call.

Atai Life Sciences N.V. (ATAI) Q3 2022 Earnings Call Transcript

Video interview with Management to be posted today at 8:30 a.m. EST

atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update

TORONTO--(BUSINESS WIRE)---- $KONEF #psychedelics--The Women in Psychedelics Network (“WIPN” or “Network”), a network of professionals from all corners of the psychedelic industry strengthening women's voices and providing opportunities to move mental health solutions forward, today announced atai Life Sciences N.V.

News for Atai Life Sciences BV Stock (ATAI)